Citation

Seeman MV. Neuropharmacology 2020; 163: e107631.

Copyright

(Copyright © 2020, Elsevier Publishing)

DOI

10.1016/j.neuropharm.2019.05.008

PMID

31077728

Abstract

BACKGROUND: Because women are often perceived as having better outcomes than men in psychotic illnesses such as schizophrenia - women are less often in hospital, have a lower suicide rate, are less often involved with the law, enjoy better relationships with family and friends - the question arises as to whether or not this apparent advantage is attributable to a gender difference in antipsychotic response.
OBJECTIVE: The aim of this paper is to critically review the quantitative and qualitative literature on gender difference in antipsychotic response sourced mainly from medical databases of the last ten years.
FINDINGS: There are theoretical reasons why women's effective doses of antipsychotics might need to be lower than guidelines recommend for men, especially as regards olanzapine and clozapine, but, because there are so many variables that impinge on antipsychotic response, it is difficult to provide definitive guidance. What is evident is that some antipsychotic side effects, weight gain for instance, are more worrisome for women than for men. It is also evident that, after menopause, women need an increase in their antipsychotic dose; other reproductive stages in women's lives require special prescribing considerations as well.
CONCLUSION: There is a science, and an art, to prescribing antipsychotics, which needs to take gender into account. This article is part of the issue entitled 'Special Issue on Antipsychotics'.

Language: en

Keywords

Humans; Gender; Female; Male; Sex Factors; Schizophrenia; Psychosis; Antipsychotics; Clozapine; Olanzapine; Psychotic Disorders; Response; Side effects; Risperidone; Antipsychotic Agents; Psychoses, Substance-Induced